Literature DB >> 10191211

Restricted low-level human antibody responses against Epstein-Barr virus (EBV)-encoded latent membrane protein 1 in a subgroup of patients with EBV-associated diseases.

P Meij1, M B Vervoort, J Aarbiou, P van Dissel, A Brink, E Bloemena, C J Meijer, J M Middeldorp.   

Abstract

Human antibody responses to latent membrane protein 1 (LMP1) in patients with Epstein-Barr virus (EBV)-related disease syndromes were analyzed in detail. Only by immunoblot analysis with purified recombinant LMP1 and by IFA on recombinant LMP1-expressing insect cells could human antibodies directed against LMP1 be detected. Low serum levels of LMP1-directed antibodies could be detected in 3 of 8 EBV-positive Hodgkin's disease patients, 3 of 40 nasopharyngeal carcinoma patients, 2 of 23 Burkitt's lymphoma patients, and 1 of 27 non-Burkitt's lymphoma patients. No LMP1-directed antibodies could be detected in healthy EBV carriers, infectious mononucleosis patients, or patients with chronic EBV disease. All sera contained significant levels of EBV antibodies directed against the immunodominant EBV proteins and peptides. From this study, it can be concluded that LMP1 is a protein with a very low immunogenicity for the humoral immune response in humans.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10191211     DOI： 10.1086/314704

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


  16 in total

1.  LMP1 association with CD63 in endosomes and secretion via exosomes limits constitutive NF-κB activation.

Authors:  Frederik J Verweij; Monique A J van Eijndhoven; Erik S Hopmans; Tineke Vendrig; Tom Wurdinger; Ellen Cahir-McFarland; Elliott Kieff; Dirk Geerts; Rik van der Kant; Jacques Neefjes; Jaap M Middeldorp; D Michiel Pegtel
Journal:  EMBO J       Date:  2011-04-28       Impact factor: 11.598

2.  Prognostic utility of anti-EBV antibody testing for defining NPC risk among individuals from high-risk NPC families.

Authors:  Kelly J Yu; Wan-Lun Hsu; Ruth M Pfeiffer; Chun-Ju Chiang; Cheng-Ping Wang; Pei-Jen Lou; Yu-Juen Cheng; Patti Gravitt; Scott R Diehl; Alisa M Goldstein; Chien-Jen Chen; Allan Hildesheim
Journal:  Clin Cancer Res       Date:  2011-03-29       Impact factor: 12.531

3.  Patterns of Interindividual Variability in the Antibody Repertoire Targeting Proteins Across the Epstein-Barr Virus Proteome.

Authors:  Zhiwei Liu; Anna E Coghill; Ruth M Pfeiffer; Carla Proietti; Wan-Lun Hsu; Yin-Chu Chien; Lea Lekieffre; Lutz Krause; Kelly J Yu; Pei-Jen Lou; Cheng-Ping Wang; Jason Mulvenna; Jaap M Middeldorp; Jeff Bethony; Chien-Jen Chen; Denise L Doolan; Allan Hildesheim
Journal:  J Infect Dis       Date:  2018-05-25       Impact factor: 5.226

4.  Purified hexameric Epstein-Barr virus-encoded BARF1 protein for measuring anti-BARF1 antibody responses in nasopharyngeal carcinoma patients.

Authors:  E K Hoebe; S H Hutajulu; J van Beek; S J Stevens; D K Paramita; A E Greijer; J M Middeldorp
Journal:  Clin Vaccine Immunol       Date:  2010-12-01

5.  Differential immunogenicity of Epstein-Barr virus latent-cycle proteins for human CD4(+) T-helper 1 responses.

Authors:  A Leen; P Meij; I Redchenko; J Middeldorp; E Bloemena; A Rickinson; N Blake
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

6.  Single-assay combination of Epstein-Barr Virus (EBV) EBNA1- and viral capsid antigen-p18-derived synthetic peptides for measuring anti-EBV immunoglobulin G (IgG) and IgA antibody levels in sera from nasopharyngeal carcinoma patients: options for field screening.

Authors:  J Fachiroh; D K Paramita; B Hariwiyanto; A Harijadi; H L Dahlia; S R Indrasari; H Kusumo; Y S Zeng; T Schouten; S Mubarika; J M Middeldorp
Journal:  J Clin Microbiol       Date:  2006-04       Impact factor: 5.948

7.  Serum antibody response to lytic and latent Epstein-Barr virus antigens in undifferentiated nasopharyngeal carcinoma patients from an area of nonendemicity.

Authors:  Rosamaria Tedeschi; Elisa Pin; Debora Martorelli; Ettore Bidoli; Alessia Marus; Chiara Pratesi; Maria Teresa Bortolin; Stefania Zanussi; Emanuela Vaccher; Riccardo Dolcetti; Paolo De Paoli
Journal:  Clin Vaccine Immunol       Date:  2007-02-28

8.  Elevated anti-Zta IgG levels and EBV viral load are associated with site of tumor presentation in endemic Burkitt's lymphoma patients: a case control study.

Authors:  Amolo S Asito; Erwan Piriou; Peter Sumba Odada; Nancy Fiore; Jaap M Middeldorp; Carole Long; Sheetij Dutta; David E Lanar; Walter G Jura; Collins Ouma; Juliana A Otieno; Ann M Moormann; Rosemary Rochford
Journal:  Infect Agent Cancer       Date:  2010-07-28       Impact factor: 2.965

9.  Characterization of ELISA detection of broad-spectrum anti-Epstein-Barr virus antibodies associated with nasopharyngeal carcinoma.

Authors:  Cindy Chang; Jaap Middeldorp; Kelly J Yu; Hedy Juwana; Wan-Lun Hsu; Pei-Jen Lou; Cheng-Ping Wang; Jen-Yang Chen; Mei-Ying Liu; Ruth M Pfeiffer; Chien-Jen Chen; Allan Hildesheim
Journal:  J Med Virol       Date:  2012-12-21       Impact factor: 2.327

10.  Novel approach to the formulation of an Epstein-Barr virus antigen-based nasopharyngeal carcinoma vaccine.

Authors:  Viviana P Lutzky; Monika Corban; Lea Heslop; Leanne E Morrison; Pauline Crooks; David F Hall; William B Coman; Scott A Thomson; Denis J Moss
Journal:  J Virol       Date:  2010-01       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.